Net Income (Loss) Attributable to Parent in USD of Astria Therapeutics, Inc. from 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Astria Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2013 to Q3 2025.
  • Astria Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$31.6M, a 29% decline year-over-year.
  • Astria Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$124M, a 24% decline year-over-year.
  • Astria Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$94.3M, a 29.3% decline from 2023.
  • Astria Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$72.9M, a 40.6% decline from 2022.
  • Astria Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$51.8M, a 73.4% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Astria Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$124M -$31.6M -$7.11M -29% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-12
Q2 2025 -$117M -$33.1M -$8.88M -36.7% Apr 1, 2025 Jun 30, 2025 10-Q 2025-11-12
Q1 2025 -$108M -$33.7M -$13.8M -69.2% Jan 1, 2025 Mar 31, 2025 10-Q 2025-11-12
Q4 2024 -$94.3M -$25.6M +$5.78M +18.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-11
Q3 2024 -$100M -$24.5M -$6.81M -38.4% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-12
Q2 2024 -$93.2M -$24.2M -$11.6M -92.4% Apr 1, 2024 Jun 30, 2024 10-Q 2025-11-12
Q1 2024 -$81.6M -$19.9M -$8.74M -78.1% Jan 1, 2024 Mar 31, 2024 10-Q 2025-11-12
Q4 2023 -$72.9M -$31.4M -$18.1M -137% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-11
Q3 2023 -$54.7M -$17.7M -$5.73M -47.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$49M -$12.6M -$1.32M -11.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-13
Q1 2023 -$47.7M -$11.2M +$4.14M +27% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-13
Q4 2022 -$51.8M -$13.3M -$3.77M -39.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-04
Q3 2022 -$48.1M -$12M -$4.13M -52.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$43.9M -$11.3M -$3.78M -50.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$40.2M -$15.3M +$155M +91% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$195M -$9.49M -$513K -5.71% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 -$194M -$7.87M +$2.99M +27.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$197M -$7.47M +$2.04M +21.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$199M -$170M -$162M -2039% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$37.3M -$8.98M -$2.37M -35.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$34.9M -$10.9M -$4.35M -66.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$30.6M -$9.51M -$2.38M -33.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$28.2M -$7.95M -$1.91M -31.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$26.3M -$6.61M -$550K -9.08% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-10
Q3 2019 -$25.7M -$6.51M -$835K -14.7% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$24.9M -$7.13M -$652K -10.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$24.3M -$6.04M +$1.61M +21.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$25.9M -$6.06M -$563K -10.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-10
Q3 2018 -$25.3M -$5.68M +$1.34M +19.1% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-10
Q2 2018 -$26.6M -$6.48M +$495K +7.1% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-10
Q1 2018 -$27.1M -$7.65M +$224K +2.84% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-10
Q4 2017 -$27.4M -$5.5M +$3.28M +37.4% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 -$30.6M -$7.02M +$1.4M +16.7% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-14
Q2 2017 -$32M -$6.97M +$2.47M +26.2% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-14
Q1 2017 -$34.5M -$7.88M +$1.54M +16.4% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-14
Q4 2016 -$36.1M -$8.78M +$828K +8.62% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 -$36.9M -$8.42M +$66K +0.78% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 -$37M -$9.45M -$1.41M -17.5% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
Q1 2016 -$35.5M -$9.42M -$2.92M -44.9% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q4 2015 -$32.6M -$9.61M Oct 1, 2015 Dec 31, 2015 10-K 2018-03-15
Q3 2015 -$8.49M -$2.46M -40.8% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 -$8.04M -$2.68M -49.9% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-11
Q1 2015 -$6.5M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
Q3 2014 -$6.03M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 -$5.36M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-13

Astria Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$94.3M -$21.4M -29.3% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-11
2023 -$72.9M -$21.1M -40.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-11
2022 -$51.8M +$143M +73.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-04
2021 -$195M -$158M -423% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-22
2020 -$37.3M -$11M -41.9% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2019 -$26.3M -$423K -1.64% Jan 1, 2019 Dec 31, 2019 10-K/A 2021-04-19
2018 -$25.9M +$1.49M +5.46% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-10
2017 -$27.4M +$8.7M +24.1% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-14
2016 -$36.1M -$3.43M -10.5% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-15
2015 -$32.6M -$10.7M -49.1% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-15
2014 -$21.9M -$3.77M -20.8% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-16
2013 -$18.1M Jan 1, 2013 Dec 31, 2013 10-K 2016-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.